In the midst of Amgen (AMGN) facing intense competition for its blockbuster products from its rivals, the pharma company posted better-than-expected second-quarter results – amidst fierce competition and growing concerns from the public to make drugs affordable. Shares of Amgen rose above 1% in the after-hours trading.
With the recent launch of new products, sales improved 4% to $6.05 billion while profits jumped 17% touching $3.83 per share due to strong product sales. Free cash flow for the quarter came in at $1.9 billion, down 9.5% compared to last year due to increased tax outgo. Selling, General & Administrative expenses increased 12% due to product launches and increased marketing costs.
The company has been witnessing a drop in revenues from old blockbuster drugs due to the launch of biosimilar from its peers. However, this is expected to be offset by the recent launches which look promising and expected to augur well for Amgen.
Related: Amgen posts top-line results for Remicade alternative in Phase 3 trial
On the product sales front, sales of cholesterol drug Repatha surged 78% due to strong demand and drugs like BLINCYTO, KYPROLIS, Prolia, and XGEVA recorded double-digit growth which is a good sign for the company. Product sales rose 2% compared to last year touching $5.68 billion.
In May, FDA has given the nod for Aimovig, a drug used for treating migraine patients is expected to be a blockbuster drug. Along the same lines, other drugs like Xgeva, Prolia, KYPROLIS, BLINCYTO, and Repatha is expected to bode well in the upcoming quarters. Amgen also has a robust pipeline with the likes of Amjevita, which is expected to hit the market in October augmenting its potential blockbuster list.
Amgen has raised the outlook for 2018 due to improved product sales and strong product pipeline. The company now estimates sales to be between $22.5 billion and $23.2 billion and adjusted EPS revised upwards in the range of $13.30 to $14. In the last 12 months, the stock price has increased above 10% and in 2018 it’s up nearly 12%.
Related: Amgen stock increases as its new migraine treatment won FDA approval
On a separate note, the biotech giant announced changes in two key leadership roles. Sean Harper who is heading R&D has announced his retirement after spending 16 years with the firm. He will be replaced by David Reese who is currently looking after Translational Sciences and Oncology. In addition, Global Commercial head Anthony Hooper is planning to retire in September 2018, and the current Chief Commercial Officer Murdo Gordon will be succeeding Hooper.
Last week, Johnson & Johnson (JNJ) reported that its Q2 results topped analyst estimates on both the top and bottom line aided by double-digit growth in Pharma business and the accelerating sales momentum in the Medical Devices business.
Most Popular
What to look for when CVS Health (CVS) reports Q3 earnings
Healthcare company CVS Health Corporation (NYSE: CVS) is all set to report earnings next week, with Wall Street expecting a mixed outcome. The company has been facing challenges in certain
eBay (EBAY): A few factors that helped drive growth in Q3 2024
Shares of eBay Inc. (NASDAQ: EBAY) stayed green on Friday. The stock has gained 32% year-to-date. The ecommerce leader delivered revenue and earnings growth for the third quarter of 2024,
CVX Earnings: Chevron reports lower revenue and profit for Q3 2024
Energy exploration company Chevron Corporation (NYSE: CVX) on Friday announced third-quarter 2024 financial results, reporting a decline in net profit and revenues. Net income attributable to Chevron Corporation dropped to